Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 18 articles: HTML format

Single Articles

June 2025
1. KAWAGUCHI Y, Hasegawa K, Kashiwabara K, Okamura Y, et al
   Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial).
   J Clin Oncol. 2025 Jun 24:JCO2402030. doi: 10.1200/JCO-24-02030.
   PubMed     Abstract available
   
   
   March 2025
2. XI M, Fu Y, Zhang Y
   Reply to: Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
   J Clin Oncol. 2025 Mar 25:JCO2500327. doi: 10.1200/JCO-25-00327.
   PubMed    
   
   
   
3. KIBE Y
   Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
   J Clin Oncol. 2025 Mar 25:JCO2402861. doi: 10.1200/JCO-24-02861.
   PubMed    
   
   
   February 2025
4. FU Y, Zhang Y, Hu D, Zhou Z, et al
   Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
   J Clin Oncol. 2025 Feb 25:JCO2402615. doi: 10.1200/JCO-24-02615.
   PubMed    
   
   
   
5. NEWMAN NB, Court CM, Parikh AA
   What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?
   J Clin Oncol. 2025 Feb 11:JCO2402541. doi: 10.1200/JCO-24-02541.
   PubMed     Abstract available
   
   
   December 2024
6. XI M, Yang Z, Hu L, Fu Y, et al
   Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.
   J Clin Oncol. 2024 Dec 18:JCO2401532. doi: 10.1200/JCO-24-01532.
   PubMed     Abstract available
   
   
   
7. MAGYAR CTJ, O'Kane GM, Aceituno L, Li Z, et al
   Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy.
   J Clin Oncol. 2024 Dec 16:JCO2400857. doi: 10.1200/JCO.24.00857.
   PubMed     Abstract available
   
   
   October 2024
8. 
   Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguan
   J Clin Oncol. 2024 Oct 10:JCO2402040. doi: 10.1200/JCO-24-02040.
   PubMed    
   
   
   August 2024
9. SHEN YC, Liu TH, Nicholas A, Soyama A, et al
   Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
   J Clin Oncol. 2024 Aug 28:JCO2400645. doi: 10.1200/JCO.24.00645.
   PubMed     Abstract available
   
   
   July 2024
10. JAIN A, Lau NS
    Liver Transplantation in Colorectal Cancer With Unresectable Liver Metastases: Disease Biology Cannot Be Ignored.
    J Clin Oncol. 2024 Jul 8:JCO2400619. doi: 10.1200/JCO.24.00619.
    PubMed    
    
    
    June 2024
11. ETTRICH TJ, Modest DP, Sinn M, Striefler JK, et al
    Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
    J Clin Oncol. 2024 Jun 6:JCO2301566. doi: 10.1200/JCO.23.01566.
    PubMed     Abstract available
    
    
    
12. KAWAZOE A, Xu RH, Garcia-Alfonso P, Passhak M, et al
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
    J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736.
    PubMed     Abstract available
    
    
    May 2024
13. SANGRO B, Galle PR, Kelley RK, Charoentum C, et al
    Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    J Clin Oncol. 2024 May 28:JCO2301462. doi: 10.1200/JCO.23.01462.
    PubMed     Abstract available
    
    
    
14. FICHTINGER RS, Aldrighetti LA, Abu Hilal M, Troisi RI, et al
    Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1799-1809.
    PubMed     Abstract available
    
    
    April 2024
15. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
    Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
    J Clin Oncol. 2024;42:1098-1101.
    PubMed    
    
    
    March 2024
16. GORDAN JD, Kennedy EB, Abou-Alfa GK, Beal E, et al
    Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745.
    PubMed     Abstract available
    
    
    January 2024
17. HUANG DQ, Hoang JK, Kamal R, Tsai PC, et al
    Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.
    J Clin Oncol. 2024 Jan 4:JCO2300757. doi: 10.1200/JCO.23.00757.
    PubMed     Abstract available
    
    
    November 2023
18. WANG G, Zhuo N, Liu Z
    Nonalcoholic Fatty Liver Disease May Be an Independent, Modifiable Risk Factor for Young-Onset Digestive Tract Cancers.
    J Clin Oncol. 2023;41:5070.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.